Dr Agarwal's Health Care shareholders approve all 7 AGM resolutions
- All seven resolutions passed at Dr Agarwal's 16th AGM held on September 21, 2026
- Shareholders approved FY26 audited financial statements with 99.93% support
- Remuneration revisions for CEO Dr Adil Agarwal and COO Dr Anosh Agarwal cleared with 99.98% approval
- Reappointment of Director Ankur Nand Thadani faced 12.30% dissent but passed with 87.70% support
- Promoter group voted 100% in favour across all agenda items
*this image is generated using AI for illustrative purposes only.
Dr. Agarwal's Health Care shareholders approved all seven resolutions at its 16th annual general meeting, including the adoption of FY26 financial statements and remuneration revisions for top executives. The virtual meeting, held on September 21, 2026, saw unanimous promoter support and overwhelming public backing for most agenda items.
The company reported a total shareholder base of 42,656 as of the record date, September 15, 2026. Of these, 30,13,60,021 votes were polled across the resolutions, representing approximately 95% of outstanding shares. Mr. Subramanian Chandrasekar served as the independent scrutinizer, confirming that all resolutions passed with the requisite majority.
Resolution Outcomes
The AGM covered governance appointments, auditor ratification, and executive compensation changes. While promoter interests voted uniformly in favour of all proposals, public institutional investors showed varying levels of dissent, particularly regarding the reappointment of Non-Executive Director Mr. Ankur Nand Thadani.
| Resolution Description | Type | Votes In Favour (%) | Votes Against (%) | Promoter Interest |
|---|---|---|---|---|
| Adoption of FY26 Financial Statements | Ordinary | 99.93% | 0.07% | No |
| Re-appointment of Dr. Anosh Agarwal (COO) | Ordinary | 99.96% | 0.04% | Yes |
| Re-appointment of Mr. Ankur Nand Thadani | Ordinary | 87.70% | 12.30% | No |
| Appointment of S.R. Batliboi & Associates | Ordinary | 99.99% | 0.00% | No |
| Remuneration Revision: Dr. Adil Agarwal (CEO) | Special | 99.98% | 0.02% | Yes |
| Remuneration Revision: Dr. Anosh Agarwal (COO) | Special | 99.98% | 0.02% | Yes |
| Ratification of Cost Auditor Remuneration | Ordinary | 100.00% | 0.00% | No |
Voting Participation
Remote e-voting was conducted from September 17 to September 20, 2026. The promoter group, holding 10,25,04,118 shares, voted 100% in favour of every resolution. Public institutional shareholders, holding 20,70,23,062 shares, participated actively, polling over 95% of their holdings.
The only resolution facing notable dissent was Item 3, the reappointment of Mr. Ankur Nand Thadani. Public institutional investors cast 3,70,38,008 votes against this proposal, resulting in a 12.30% dissent rate among total votes polled. However, strong support from non-institutional public shareholders ensured the resolution passed with an overall 87.70% approval.
All other resolutions received near-unanimous support from public shareholders, with dissent rates below 0.2% for financial adoption and auditor appointments.
Historical Stock Returns for Dr. Agarwal's Health Care
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.73% | -3.89% | -7.97% | +8.01% | -9.92% | +16.49% |
What specific strategic initiatives or performance metrics are driving the approved remuneration revisions for CEO Dr. Adil Agarwal and COO Dr. Anosh Agarwal?
How might the 12.30% dissent from public institutional investors regarding Mr. Ankur Nand Thadani's reappointment influence future corporate governance practices or board composition at Dr. Agarwal's Health Care?
Given the near-unanimous approval of FY26 financial statements, what key growth drivers or margin improvements should investors expect in the upcoming fiscal year?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
